Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afatinib in NSCLC with EGFR or HER2 mutations (DARWIN1)
NCT02183883Phase 2Completed
- Sponsor
- University College London
- Start
- Dec 2016
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of afatinib in non-small cell lung cancer (NSCLC), sponsored by University College London. Started Dec 2016; status: completed.
02
Drugs
afatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02183883.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02183883.